The H.U. Group is engaged in R&D activities to provide new value, looking ahead to the medical and healthcare needs of the future.To complement the technological and development capabilities in laboratory testing and diagnostics that we have accumulated since our foundation, in 2017 we established Miraca Research Institute G.K. (currently H.U. Group Research Institute G.K.:HRI). Since then we have worked to generate a steady stream of innovation through a diverse range of activities not bound by conventional approaches to R&D.

H.U. Group is driving collaboration among its R&D organizations across the Group. For example, HRI incorporates diverse new technologies at an early stage and promotes the development of products and services in emerging technological fields. At the same time, the R&D division of the IVD business has built technological foundations in diagnostic reagent and system development. By combining with the expertise of the R&D division of the LTS business in evaluating and introducing new technologies, the Group can accelerate the development and market introduction of distinctive new products and innovative services. While each R&D organization continues to focus on its respective activities, they strengthen collaboration in strategy, issues, and resources, creating new value by leveraging the Group’s strengths and contributing further to society, medicine, and healthcare.

The medical and healthcare environment is changing rapidly and becoming increasingly complex due to factors such as the advent of personalized medicine, advances in digitalization, automation, and AI technology, and the restricted access to medical care following the outbreak of the pandemic. The H.U. Group will put in place human resources and technological foundations to enable a swift response to these major changes in the operating environment. To lead the change within the industry, we are also actively promoting R&D activity and human resource development across a diverse range of research fields.
By also actively promoting mergers and acquisitions, business alliances, and open innovation, and by utilizing and adopting the technology and business platforms of universities, medical and research institutions, enterprises, and other external organizations in Japan and overseas, we aim to bring to market products and services of value in the shortest time possible.